IRIS
MOR, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.714
AS - Asia 11.348
EU - Europa 9.077
SA - Sud America 1.601
AF - Africa 593
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 35.352
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.374
SG - Singapore 4.182
CN - Cina 3.202
VN - Vietnam 1.811
IT - Italia 1.779
FI - Finlandia 1.433
IE - Irlanda 1.295
BR - Brasile 1.248
SE - Svezia 1.146
DE - Germania 944
HK - Hong Kong 848
UA - Ucraina 652
ZA - Sudafrica 397
FR - Francia 391
NL - Olanda 356
TR - Turchia 287
GB - Regno Unito 286
CA - Canada 214
IN - India 205
RU - Federazione Russa 189
AT - Austria 188
BD - Bangladesh 126
AR - Argentina 122
CI - Costa d'Avorio 90
BE - Belgio 86
JP - Giappone 85
IQ - Iraq 76
PL - Polonia 75
ES - Italia 73
KR - Corea 73
MX - Messico 71
ID - Indonesia 66
EC - Ecuador 56
CZ - Repubblica Ceca 49
PK - Pakistan 47
PH - Filippine 46
TH - Thailandia 41
CO - Colombia 39
VE - Venezuela 39
JO - Giordania 29
CL - Cile 28
MA - Marocco 28
UZ - Uzbekistan 28
LT - Lituania 27
PY - Paraguay 25
SA - Arabia Saudita 22
TW - Taiwan 20
KE - Kenya 18
MY - Malesia 18
UY - Uruguay 16
PE - Perù 15
IL - Israele 14
NP - Nepal 14
AZ - Azerbaigian 13
RO - Romania 13
TN - Tunisia 13
ET - Etiopia 12
HU - Ungheria 12
EG - Egitto 11
HN - Honduras 11
HR - Croazia 11
OM - Oman 11
PA - Panama 10
IR - Iran 9
BO - Bolivia 8
BY - Bielorussia 8
DZ - Algeria 8
KG - Kirghizistan 8
PS - Palestinian Territory 8
SY - Repubblica araba siriana 8
AL - Albania 7
DO - Repubblica Dominicana 7
EU - Europa 7
KZ - Kazakistan 7
LB - Libano 7
RS - Serbia 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
BG - Bulgaria 6
CH - Svizzera 6
CR - Costa Rica 6
NI - Nicaragua 6
NO - Norvegia 6
EE - Estonia 5
JM - Giamaica 5
MD - Moldavia 5
QA - Qatar 5
AO - Angola 4
CY - Cipro 4
GE - Georgia 4
LU - Lussemburgo 4
LV - Lettonia 4
SI - Slovenia 4
SN - Senegal 4
BH - Bahrain 3
GR - Grecia 3
GY - Guiana 3
MN - Mongolia 3
SK - Slovacchia (Repubblica Slovacca) 3
TJ - Tagikistan 3
Totale 35.313
Salva come PNG Salva come JPEG
Città #
Singapore 2.099
Ashburn 1.487
Chandler 1.285
Dublin 1.285
San Jose 1.106
Dallas 980
Hong Kong 801
Jacksonville 753
Beijing 752
Santa Clara 750
Parma 573
Ho Chi Minh City 565
Dearborn 456
Ann Arbor 440
Boardman 420
Hanoi 388
Johannesburg 371
Nanjing 319
Los Angeles 294
Lauterbourg 250
Princeton 248
New York 246
Munich 241
Izmir 233
Shanghai 226
Wilmington 190
Hefei 179
San Mateo 162
Helsinki 156
Vienna 152
São Paulo 126
Toronto 117
Milan 114
Bremen 113
Shenyang 109
Columbus 108
Moscow 98
Nanchang 93
Abidjan 90
Jinan 88
Hebei 86
Kunming 84
Buffalo 81
Haiphong 79
Turku 77
Bologna 76
Brussels 76
Da Nang 76
Council Bluffs 74
The Dalles 72
Tokyo 70
Frankfurt am Main 69
Seattle 65
Düsseldorf 63
London 63
Changsha 62
Des Moines 60
Warsaw 58
Guangzhou 55
Jiaxing 49
Brooklyn 47
Montreal 47
Tianjin 47
Jakarta 46
Modena 45
Pune 45
Seoul 45
Houston 43
Chicago 42
Phoenix 42
Brescia 38
Rio de Janeiro 38
Woodbridge 38
Atlanta 37
Stockholm 36
Chennai 35
Orem 35
Denver 34
Fremont 33
Nuremberg 33
Baghdad 30
Belo Horizonte 30
Norwalk 30
San Francisco 30
Zhengzhou 29
Dhaka 26
Amman 25
Biên Hòa 25
Can Tho 25
Poplar 25
Amsterdam 24
Grafing 24
Hangzhou 24
Ankara 23
Brno 22
Tashkent 22
Curitiba 21
Mexico City 21
Porto Alegre 21
Fuzhou 20
Totale 21.161
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 268
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 259
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 240
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 240
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 232
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 228
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 224
2-Aminobenzimidazoles as new potent H3-antagonists 223
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 217
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 216
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 215
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 213
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 209
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 205
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 205
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 205
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 203
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 200
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 198
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 197
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. 197
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 196
Aminobenzimidazoles as new potent H3-antagonists 195
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 194
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 193
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 192
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 192
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 190
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 188
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 186
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 182
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 182
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 181
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 178
5-benzylidene-hydantoins as new inhibitors of cell proliferation 177
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 176
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo 176
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 176
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 174
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 174
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 174
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 174
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 174
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 172
Functional modulation of the human gut microbiome by bacteria vehicled by cheese 171
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 167
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 167
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 167
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 166
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 163
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 163
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 162
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 162
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility 161
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 161
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 160
3-Aminoazetidin-2-one Derivatives asN-Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration 159
Steps towards sustainable solid phase peptide synthesis: use and recovery ofN-octyl pyrrolidone 159
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 157
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 157
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 155
Chiral NMR discrimination of the diastereoisomeric salts of the H(3)-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. 154
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 154
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 153
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 152
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 149
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 149
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 149
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 149
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 148
Antioxidant and cytoprotective activity of indole derivatives related to melatonin 148
Biological studies on 1,2-benzisothiazole derivatives. V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation 148
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 148
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 147
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 147
Palladium Catalyst Recycling for Heck-Cassar-Sonogashira Cross-Coupling Reactions in Green Solvent/Base Blend 147
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 146
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 145
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 145
Mannich base derivatives as novel EGFR irreversible inhibitors 145
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 145
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 145
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 144
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 144
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 143
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 143
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 142
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 141
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 140
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 139
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 139
Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. 139
Brain Pharmacokinetics of Non-Imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrospray-Mass Spectrometry and ex vivo Binding Study in Rats 138
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 138
ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS 137
Totale 17.589
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021315 0 0 0 0 0 0 0 0 0 45 213 57
2021/20221.311 24 37 14 121 85 40 149 175 91 102 90 383
2022/20235.095 551 503 311 392 486 607 46 313 1.575 60 188 63
2023/20241.980 109 148 56 68 145 457 166 159 78 124 201 269
2024/20256.618 169 350 436 424 600 739 303 354 836 650 590 1.167
2025/202613.571 1.235 1.584 1.832 1.405 1.951 817 1.557 449 1.750 991 0 0
Totale 35.735